Follow this preprint
Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Yumiko Saga, Hiroshi Yamada, Yoshihiro Yoshida, Yusuke Takegoshi, Makito Kaneda, Yushi Murai, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Hideki Niimi, Yoshihiro Yamamoto
doi: https://doi.org/10.1101/2022.11.15.22282328
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Hitoshi Kawasuji
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yoshitomo Morinaga
bDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
cClinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan
Hideki Tani
bDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
dDepartment of Virology, Toyama Institute of Health, Toyama, Japan
Yumiko Saga
bDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
dDepartment of Virology, Toyama Institute of Health, Toyama, Japan
Hiroshi Yamada
bDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yoshihiro Yoshida
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yusuke Takegoshi
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Makito Kaneda
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yushi Murai
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Kou Kimoto
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Akitoshi Ueno
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yuki Miyajima
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Kentaro Nagaoka
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Chikako Ono
eLaboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan
fLaboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan
Yoshiharu Matsuura
eLaboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan
fLaboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan
Hideki Niimi
cClinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan
gDepartment of Clinical Laboratory and Molecular Pathology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yoshihiro Yamamoto
aDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
cClinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan

Data Availability
The authors confirm that data supporting the findings of this study are available within the article.
Posted November 18, 2022.
Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Yumiko Saga, Hiroshi Yamada, Yoshihiro Yoshida, Yusuke Takegoshi, Makito Kaneda, Yushi Murai, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Hideki Niimi, Yoshihiro Yamamoto
medRxiv 2022.11.15.22282328; doi: https://doi.org/10.1101/2022.11.15.22282328
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (423)
- Allergy and Immunology (746)
- Anesthesia (219)
- Cardiovascular Medicine (3236)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13255)
- Forensic Medicine (19)
- Gastroenterology (891)
- Genetic and Genomic Medicine (5067)
- Geriatric Medicine (471)
- Health Economics (773)
- Health Informatics (3190)
- Health Policy (1129)
- Hematology (423)
- HIV/AIDS (1005)
- Medical Education (468)
- Medical Ethics (126)
- Nephrology (513)
- Neurology (4815)
- Nursing (254)
- Nutrition (716)
- Oncology (2485)
- Ophthalmology (704)
- Orthopedics (279)
- Otolaryngology (337)
- Pain Medicine (320)
- Palliative Medicine (89)
- Pathology (531)
- Pediatrics (1282)
- Primary Care Research (550)
- Public and Global Health (7375)
- Radiology and Imaging (1671)
- Respiratory Medicine (971)
- Rheumatology (473)
- Sports Medicine (416)
- Surgery (534)
- Toxicology (69)
- Transplantation (233)
- Urology (199)